Starting Treatment With Agonist Replacement Therapies Follow-up Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01592461 |
Recruitment Status :
Completed
First Posted : May 7, 2012
Last Update Posted : August 8, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of the study is to conduct a follow-up of substance abuse patients (n=1,269) about 2 to 5 years since they were originally recruited from 8 substance abuse treatment clinics (located in 5 states) to participate in a prior clinical trial study called "START" (Starting Treatment with Agonist Replacement Therapies). The START Follow-up Study will be conducted over 5 years and will involve three follow-up interviews with START participants.
The specific aims of the START Follow-up Study are as follows.
- To determine longer-term outcomes of Suboxone versus methadone treatment received in the START
- To investigate patient and treatment factors associated with post-START treatment access, utilization, and outcomes among Suboxone and methadone patients
- To explore other correlates of the long-term outcomes among START patients.
Condition or disease |
---|
Opioid Dependence |

Study Type : | Observational |
Actual Enrollment : | 877 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | START Follow-up Study (NIDA CTN Protocol 0050) |
Study Start Date : | September 2010 |
Actual Primary Completion Date : | August 2016 |
Actual Study Completion Date : | August 2016 |

- Opioid use as determined by the Timeline Follow Back measure [ Time Frame: from 2006-2009 to 2011-2016 ]Opiate use over approximately ten years time period
- mortality [ Time Frame: from 2006-2009 to 2011-2016 ]Rate of mortality over approximately ten years time period

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- To be eligible to participate in the study, individuals must have participated in CTN-0027 START.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01592461
United States, California | |
Matrix Institute on Addictions | |
Los Angeles, California, United States, 90016 | |
Bi-Valley Medical Clinic, Inc. | |
Sacramento, California, United States, 95838 | |
BAART Programs | |
San Francisco, California, United States, 94102 | |
United States, Connecticut | |
Hartford Dispensary | |
Hartford, Connecticut, United States, 06120 | |
Yale University School of Medicine | |
New Haven, Connecticut, United States, 06510 | |
United States, Oregon | |
CODA, Inc. | |
Portland, Oregon, United States, 97214 | |
United States, Pennsylvania | |
NET Steps | |
Philadelphia, Pennsylvania, United States, 19137 | |
United States, Washington | |
Evergreen Treatment Services | |
Seattle, Washington, United States, 98134 |
Principal Investigator: | Yih-Ing Hser, Ph.D. | University of California, Los Angeles |
Responsible Party: | Yih-Ing Hser, Professor, University of California, Los Angeles |
ClinicalTrials.gov Identifier: | NCT01592461 |
Other Study ID Numbers: |
CTN-0050 U10DA013045 ( U.S. NIH Grant/Contract ) |
First Posted: | May 7, 2012 Key Record Dates |
Last Update Posted: | August 8, 2016 |
Last Verified: | August 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Deidentified data will be shared via NIDA Clinical Trials Network Website |
Substance abuse treatment outcomes Opioid dependence Suboxone Methadone |
Opioid-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders |